Katelyn O'Brien, PharmD, BCPS, CDCES, BC-ADM

Articles by Katelyn O'Brien, PharmD, BCPS, CDCES, BC-ADM

Team-Based Diabetes Care: A Panel on Improving Outcomes, Access, and Education

ByJennifer Goldman, PharmD, RPh, CDCES, BC-ADM, FCCP,Katelyn O'Brien, PharmD, BCPS, CDCES, BC-ADM,Natalie Bellini, DNP, FNP-BC, BC-ADM,Diana Isaacs, PharmD, BCPS, BC-ADM, BCACP, CDCES, FADCES, FCCP,Kristine Batty, PhD, APRN, BC-ADM, CDCES, FADCES,Luke Halpern, Associate Editor

July 16th 2026

A panel of pharmacists and nurse practitioners discussed how interdisciplinary diabetes teams divide technology education, medication management, and follow-up care.

Health care professionals attending a medical conference presentation -- Image credit: tsuguliev | stock.adobe.com

SGLT2 Inhibitors, Diabetes Tech, and Hypertension Take Center Stage at the September NEIAP Annual Forum

ByKatelyn O'Brien, PharmD, BCPS, CDCES, BC-ADM,Gillian McGovern, Editor

July 7th 2026

Katelyn O'Brien, PharmD, BCPS, CDCES, BC-ADM, discusses the New England Institute of Ambulatory Care Pharmacists (NEIAP) Annual Forum and previews key topics of discussion.

NEIAP Is Evolving to Meet the Changing Needs of Ambulatory Care Pharmacy

ByKatelyn O'Brien, PharmD, BCPS, CDCES, BC-ADM,Gillian McGovern, Editor

July 6th 2026

In addition to explaining how NEIAP has evolved over time, Katelyn O'Brien, PharmD, BCPS, CDCES, BC-ADM, previews key topics at the upcoming September meeting.

Pharmacist Management of Alpelisib-Associated Hyperglycemia

ByMeissane Benbrahim, PharmD,David Hughes, PharmD, BCOP,Katelyn O'Brien, PharmD, BCPS, CDCES, BC-ADM

July 23rd 2020

The selection of an agent for hyperglycemia management requires knowledge of both the efficacy and the potential adverse effects of each possible agent, so choosing the best therapy for any given patient can be complicated.